Participating Faculty: Evaluating the Role of Incretin-Based Therapies in the Management of Type 2 Diabetes

Evaluating the Role of Incretin-Based Therapies in the Management of Type 2 Diabetes

This supplement to The American Journal of Managed Care reviews available comparative effectiveness research related to therapies for type 2 diabetes mellitus (T2DM); discusses differences between the glucagon-like peptide-1 (GLP-1) receptor agonists and the dipeptidyl peptidase-4 (DPP-4) inhibitors; and describes in detail the clinical evidence supporting liraglutide and its role in the treatment of T2DM.

Faculty

Andrew Ahmann, MD

Professor of Medicine

Department of Medicine: Endocrinology, Diabetes & Clinical Nutrition

Director

Harold Schnitzer Diabetes Health Center

Oregon Health & Science University

Portland, Oregon

Bruce Bode, MD, FACE

Associate Professor of Medicine

Emory University School of Medicine

Atlanta Diabetes Associates

Atlanta, Georgia

David Calabrese, RPh, MHP

Chief Clinical Officer

MedMetrics Health Partners

Assistant Clinical Professor

Bouvé College of Pharmacy and Allied Health Sciences

Northeastern University

Boston, Massachusetts

Faculty Disclosures

These faculty have disclosed the following relevant commercial financial relationships or affiliations in the past 12 months.

Andrew Ahmann, MD

Advisory board/consultant: Novo Nordisk

Grants: Amylin, GlaxoSmithKline, Lilly, Mankind, Medtronic

Honoraria/lectureship: American Diabetes Association, Lilly, Medical Education Resources, Merck

Bruce Bode, MD, FACE

Advisory board/consultant: Novo Nordisk, sanofi-aventis

Grants: GlaxoSmithKline, Lilly, Novo Nordisk

Honoraria/lectureship/conference attendance: Lilly, Novo Nordisk

David Calabrese, RPh, MHP has nothing to disclose.

Signed disclosures are on file at the office of The American Journal of Managed Care, Plainsboro, New Jersey.

Evaluating the Role of Incretin-Based Therapies in the Management of Type 2 Diabetes

Funding for the development of this supplement was provided by Novo Nordisk.

The contents of this supplement may include information regarding the use of products that may be inconsistent with or outside the approved labeling for these products in the United States. Physicians should note that the use of these products outside current approved labeling is considered experimental and are advised to consult prescribing information for these products.

Download PDF: Participating Faculty: Evaluating the Role of Incretin-Based Therapies in the Management of Type 2 Diabetes